Strategic R&D Abcore Fortis Life Sciences specializes in antibody discovery using phage display and single-domain antibodies, offering a strong platform for collaborations in early-stage drug development and translational research with large pharma partners.

NK Cell Library The launch of AbNano, a VHH library derived from peripheral NK cells, creates a new opportunity to target complex NK-associated receptors and translational programs, appealing to partners focused on immuno-oncology and immune modulation.

Collaborative Deals Recent partnerships and investments, including collaboration with Deliver Bio and Astraea Bio, indicate a readiness to co-develop targeted delivery and multi-omics applications, suggesting opportunities for joint grant-funded projects and shared risk research initiatives.

Technical Differentiation The use of both naïve and immunized libraries, coupled with CHEMISTRY-enabled LFA kits with enhanced sensitivity, positions the company to pursue high-value diagnostics, translational assays, and rapid screening programs for pharma and diagnostic customers.

Financial Target With reported revenue in the mid-range of tens of millions and a lean employee base, there is appetite for scalable contract research, sponsored discovery, and technology licensing deals that leverage their compact operational model to attract mid-to-large biopharma clients seeking efficient outsourcing partners.